High-Dose Sequential Chemotherapy with Rituxan® is Superior to CHOP-R for Poor Risk Follicular Lymphoma

Researchers from Italy have reported that high-dose sequential therapy with Rituxan results in a higher remission rate when compared to CHOP-R for the treatment of patients with poor risk follicular lymphoma. The details of this multicenter randomized trial were presented at the 2006 meeting of the American Society of Hematology.



Patients with follicular lymphoma often receive moderate dose chemotherapy until they fail to respond. Then, many receive an autologous transplant as salvage therapy. A previous study by the same Italian researchers showed that high-dose chemotherapy produced complete molecular remissions in 61% of patients and that these patients had an 85% DFS at 54 months (see first item in related news).



The current study was a randomized trial involving 136 poor risk patients with FL. They were randomly allocated to receive 6 cycles of CHOP-R or an intensive induction regimen that included 3 phases: (1) 2 APO and 2 DHAP courses, (2) etoposide cyclophosphamide and Rituxan followed by stem cell harvest and (3) high-dose chemotherapy with mitoxantrone and Alkeran® (melphalan) with stem cell infusion. This was a crossover study and patients who failed R-CHOP could receive Rituxan supplemented high-dose sequential chemotherapy.
There were 4 toxic deaths; 2 in each arm. Disease progression occurred in 28% of the R-CHOP patients and 10% of the high-dose group. Two thirds of the patients failing R-CHOP crossed over to receive high-dose sequential therapy and 73% achieved a CR. Event-free survival at 40 months was approximately 65% for the high-dose group and 20% for the CHOP group. However, 83% of patients survived at 36 months in both arms. A stable molecular remission was achieved in 28% of R-CHOP patients and 78% of the high-dose group.



Ladetto M, de Marco F, Benedetti F, et al. Clinical and molecular results of the multicenter randomized GITMO-IIL trial in poor risk follicular lymphoma (FL) at diagnosis: Rituximab-supplemented high-dose sequential chemotherapy (R-HDS) is superior to CHOP-R in molecular remissions rate, EFS and PFS. Blood 2006;108:101a, abstract 325.

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap